CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept
Geeta Karadkhele(Emory Healthcare), Christian P. Larsen(Emory University Hospital), Thomas C. Pearson(Emory Healthcare), Weiwen Zhang(Ministry of Education of the People's Republic of China), Julien Hogan(Assistance Publique – Hôpitaux de Paris), Wairimu Magua(Emory Healthcare), Marshall Lyon(Office of Infectious Diseases), Stephen O. Pastan(Emory University), Aneesh K. Mehta(Emory University), I.R. Badell(Emory University)
Cited by 81
Related Papers
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
|Nature|1996|1.5k
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
|The Journal of Experimental Medicine|1997|802
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Heterologous immunity provides a potent barrier to transplantation tolerance
|Journal of Clinical Investigation|2003|571
Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)
|American Journal of Transplantation|2010|566